ALK and non-small cell lung carcinoma: The data showed improved PFS associated with the additional of atezolizumab to the bevacizumab, carboplatin, and paclitaxel combination in EGFR and ALK altered NSCLC (9.7 months vs. 6.1 months), providing direct evidence supporting the use of the regimen in this population (38).